Cotiviti nears $3 billion deal to acquire Edifecs, rejecting higher bid from UnitedHealth. Antitrust concerns cited.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Evercore ISI analyst Glenn Schorr maintained a Buy rating on KKR & Co (KKR – Research Report) yesterday and set a price target of $165.00.

Q4 2024 Earnings Call Transcript February 4, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.32, ...

J.P. Morgan analyst Richard Shane maintained a Buy rating on Kkr Real Estate Finance (KREF – Research Report) yesterday and set a price target ...

XOi, a leading provider of jobsite-focused technology solutions for the field service ecosystem, today announced the ...

KKR-backed healthcare data company Cotiviti is close to securing a deal to buy smaller rival Edifecs for just over $3bn, after it opted against accepting a higher bid from UnitedHealth Group out of ...

Tech groups and clean power builders are partnering to co-locate data centers and power generation to reduce permitting and ...

It was the unexpected World War One treatment centre created by a woman determined to do her bit. Florence Rudge's home ended ...

Chakravarthy made a comeback to the Indian unit in the home series against Bangladesh in October 2024 and is the leading ...

The US-based private equity firm and Mitsubishi are finalising details of a transaction that could be announced as soon as ...

BAIN Capital is nearing a deal to buy Mitsubishi Chemical Group’s pharmaceutical unit, sources familiar with the matter said, ...